H. Bøggild (Aalborg, Denmark)
Aalborg UniversityAuthor Of 1 Presentation
54P - Overweight and prognosis in triple-negative breast cancer patients: a systematic review and meta-analysis
Abstract
Background
The purpose is to conduct a systematic review and meta-analysis evaluating the impact of overweight on prognosis in triple-negative breast cancer (TNBC) patients.
Methods
Systematic searches were conducted in PubMed and Embase using variations of the search terms triple-negative breast neoplasms (population), overweight and/or obesity (exposure), and prognosis (outcome). Data were extracted from longitudinal observational studies, which used survival statistics with hazard ratios (HRs) to examine disease-free survival and/or overall survival according to body mass index measured at the time of diagnosis of TNBC. Overweight was defined using the World Health Organization guidelines. Guided by the Meta-analysis of Observational Studies in Epidemiology (MOOSE) checklist, study data were extracted and study quality assessed with the Newcastle-Ottawa Scale independently by two authors. The effect sizes (HRs) were combined with random-effects models, and the results were evaluated and adjusted for possible publication bias.
Results
The study selection process identified 11 eligible studies of 5,556 TNBC patients. The pooled estimates indicated that, relative to non-overweight, overweight was associated with both shorter disease-free survival (HR=1.33; 95%CI: 1.13–1.58) and shorter overall survival (HR=1.39; 95%CI: 1.15-1.69). Supplementary Bayesian meta-analyses showed strong evidence for non-zero effects, with the alternative hypothesis being 12.7 and 13.5 times more likely than the null-hypothesis for disease-free survival and overall survival, respectively.
Conclusions
Relative to non-overweight, overweight was associated with a shorter disease-free and overall survival among TNBC patients.
Legal entity responsible for the study
Aarhus University.
Funding
Slagtermester Max Wørzner og Hustru Wørzners Memorial Foundation, Health Research Foundation of Central Denmark Region, Aarhus University.
Disclosure
R. Zachariae: Honoraria (self), Shareholder/Stockholder/Stock options, None of this had any role in the design, data collection, analysis, or preparation of the manuscript: Novo Nordisk. S. Borgquist: Honoraria (self), Travel/Accommodation/Expenses, None of this had any role in the design, data collection, analysis, or preparation of the manuscript: Pfizer; Honoraria (self), Travel/Accommodation/Expenses, None of this had any role in the design, data collection, analysis, or preparation of the manuscript: Roche. All other authors have declared no conflicts of interest.